Early initiation of menopausal hormone therapy was not significantly associated with myocardial infarction risk compared with never use (OR 0.87; 95% CI 0.58-1.30).
Case-Control (n=846)
Effect estimate: OR 0.87 (95% CI 0.58-1.30)
OBJECTIVE: This study aims to assess whether the timing of menopausal hormone therapy initiation in relation to onset of menopause and hormone therapy duration is associated with myocardial infarction risk. METHODS: This study was based on the Stockholm Heart Epidemiology Program, a population-based case-control study including 347 postmenopausal women who had experienced a nonfatal myocardial infarction and 499 female control individuals matched for age and residential area. Odds ratios (with 95% CIs) for myocardial infarction were calculated using logistic regression. RESULTS: Early initiation of hormone therapy (within 10 y of onset of menopause or before age 60 y), compared with never use, was associated with an odds ratio of 0.87 (95% CI, 0.58-1.30) after adjustments for lifestyle factors, body mass index, and socioeconomic status. For late initiation of hormone therapy, the corresponding odds ratio was 0.97 (95% CI, 0.53-1.76). For hormone therapy duration of 5 years or more, compared with never use, the adjusted odds ratio was 0.64 (95% CI, 0.35-1.18). For hormone therapy duration of less than 5 years, the odds ratio was 0.97 (95% CI, 0.63-1.48). CONCLUSIONS: Neither the timing of hormone therapy initiation nor the duration of therapy is significantly associated with myocardial infarction risk.
Carrasquilla et al. (Tue,) conducted a case-control in Myocardial infarction (n=846). Menopausal hormone therapy vs. Never use was evaluated on Myocardial infarction risk (OR 0.87, 95% CI 0.58-1.30). Early initiation of menopausal hormone therapy was not significantly associated with myocardial infarction risk compared with never use (OR 0.87; 95% CI 0.58-1.30).